Head-to-head · Cost-Efficiency Index
Hers vs Coivas
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Hers
Cost-first shoppers who want brand-name FDA-approved GLP-1 access with a mainstream telehealth name.
Visit HersCoivas
Shoppers wanting a named, verifiable prescribing physician (NPI-checkable) behind a nationwide compounded GLP-1 service.
Visit CoivasThe verdict
Hers and Coivas tie on the Cost-Efficiency Index at 58/100, so neither wins outright on the numbers. For most shoppers we'd start with Hers (ranked #279, a hair above #284) — Cost-first shoppers who want brand-name FDA-approved GLP-1 access with a mainstream telehealth name. But Coivas is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Hers.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Hers | Coivas |
|---|---|---|
| Cost-Efficiency Index | 58/100 | 58/100 |
| Semaglutide / mo | $348/mo (brand Wegovy, plus a separate fee) | $119/mo (starting dose, compounded) |
| Tirzepatide / mo | $448/mo (brand Zepbound, plus a separate fee) | $199/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $4,176 | $1,428 |
| Tirzepatide / yr (modeled) | $5,376 | $2,388 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #279 | #284 |
Hers
58/100Where the value is
- Sells only FDA-approved branded medications (Wegovy, Zepbound, Ozempic, Mounjaro) rather than compounded versions
- Multiple formats per drug (pill vs pen/vial), including a newer pill option and microdosing plan
- Large, publicly traded parent (Hims & Hers Health) with an established clinical/support infrastructure
The tradeoffs
- The advertised 'From $X/mo' price is medication-only — a mandatory membership fee ($39 first month, then $149/mo, billed separately) is layered on top and roughly doubles the real steady-state monthly cost
- No compounded, lower-cost semaglutide/tirzepatide option was found on the current site
Regulatory note: the FDA issued a warning letter to Hims & Hers Health, Inc. dba Hers in September 2025. We still list and link to Hers; you should know the letter is on the public record before you decide.
Coivas
58/100Where the value is
- Named prescribing physician with checkable NPI (Dr. Sean Arora, NPI 1841729449)
- LegitScript approval seal displayed
- Claims availability in all 50 states
The tradeoffs
- 'Starting at' pricing could not be confirmed as the genuine ongoing rate -- pricing subpages were unreachable (404)
- No single named compounding pharmacy -- varies by location/medication
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.